Miguel, J., Araujo, L. H. and Costa, R. (2020) “Cost-effectiveness of erlotinib compared to gefitinib for NSCLC with EGFR mutations at the Inca”, Jornal Brasileiro de Economia da Saúde, 12(1), pp. 8–15. doi: 10.21115/JBES.v12.n1.p8-15.